CORE--HYBRIDOMA

核心--杂交瘤

• 批准号: 7142516
• 负责人: Robert C Young
• 金额: $ 6.1万
• 依托单位: FOX CHASE CANCER CENTER
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-09-10 至 2010-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7142516
• 关键词: biomedical facility; hybridomas; immunologic substance development /preparation; monoclonal antibody; neoplasm /cancer; neoplasm /cancer immunology

Monoclonal antibodies (mAb) are fundamental tools for the advancement of biomedical research and the understanding, detection and treatment of cancer. The Fox Chase Cancer Center (FCCC) Hybridoma Facility has the expertise and resources both for the custom generation of hybridomas and for the production and purification of mAb. The Facility enables a diverse group of scientists, especially those unfamiliar with the specialized methods required to produce hybridomas, to obtain valuable antibody reagents efficiently and economically. As a reflection of this assistance, eight laboratories in the Center have become new users of the Facility since 1999. In addition, the number of laboratories storing cells in the liquid nitrogen freezers maintained by the Facility expanded from 23 to 26, thus reducing the duplication of these freezers in individual laboratories. Currently, investigators outside the Immunobiology Program comprise the major user group in the Center. Overall, 26 investigators with peer-reviewed funding (25% increase since 1999) participating in 8 of the 11 Research Programs, representing all three Divisions of the Center, use the Facility. In 2003, peer-reviewed usage of the Facility was 98%. Since 1999, new Facility services include in vitro production of high-titer mAb (a goal of the last review), quantitation of in vitro murine mAb production by ELISA and monitoring of in vitro production of rabbit, rat and hamster mAb by slide-electrophoresis, purification of mAb, polyacrylamide gel electrophoresis to determine the purity of purified mAb, labeling mAb with fluorescent dyes and production of recombinant IL-6. Demand since the last review has also grown for older services including hybricloma cloning (32% increase) and mAb isotyping (30% increase). Services provided are at near capacity for the Facility staff (1.5 FTE). A future goal of the Facility is to improve the efficiency and cost-effectiveness of producing rabbit hybridomas, as rabbits usually produce high affinity antibodies and are the first choice among many investigators for raising antibodies. The Facility will also generate and select a panel of rat and rabbit monoclonal antibodies that recognize epitope tags that are often engineered into recombinant proteins. Such tag-specific mAb could be used for detection and purification of tagged proteins when a protein-specific mAb is not yet available and would also be useful for sandwich-ELISA.

单克隆抗体（MAB）是生物医学发展的基本工具 研究以及癌症的理解，检测和治疗。 FOX CHASE癌症中心（FCCC）杂交瘤设施具有定制杂交瘤的专业知识和资源，以及MAB的生产和纯化。该设施使一群科学家，尤其是那些不熟悉产生杂交瘤所需的专门方法的科学家，以有效和经济地获得有价值的抗体试剂。为了反映这种援助，自1999年以来，该中心的八个实验室已成为该设施的新用户。此外，该设施维护的液氮冻结剂中存储细胞的实验室数量从23个扩展到26，从而减少了这些冰柜在个别实验室中的重复。目前，免疫生物学计划之外的调查人员包括该中心的主要用户组。总体而言，有26名接受同行评审资金的调查员（自1999年以来增加了25％）参加了11项研究计划中的8个，代表该中心的所有三个部门，都使用该设施。 2003年，对该设施进行同行评审的使用率为98％。 Since 1999, new Facility services include in vitro production of high-titer mAb (a goal of the last review), quantitation of in vitro murine mAb production by ELISA and monitoring of in vitro production of rabbit, rat and hamster mAb by slide-electrophoresis, purification of mAb, polyacrylamide gel electrophoresis to determine the purity of purified mAb, labeling mAb with fluorescent dyes and production of recombinant IL-6。自上次审查以来，对较旧服务的需求也增长了，包括杂交瘤克隆（增加32％）和MAB同型（增长30％）。提供的服务对于设施人员（1.5 FTE）的身份几乎是能力。该设施的未来目标是提高产生兔杂交瘤的效率和成本效益，因为兔子通常会产生高亲和力抗体，并且是许多提高抗体的研究者的首选。该设施还将生成并选择一组大鼠和兔子单克隆抗体，这些抗体识别通常被设计为重组蛋白的表位标签。当蛋白质特异性mAb尚未可用时，这种特异性的mAb可用于检测和纯化标记蛋白，并且对于三明治 - elisa也很有用。